22:29 , Sep 21, 2018 |  BC Extra  |  Company News

Management tracks: Ex-MiMedx execs to lose compensation

MiMedx Group Inc. (NASDAQ:MDXG) said it will treat four resignations announced this summer, including that of former Chairman and CEO Parker Petit, as "for cause" terminations. The regenerative medicine and biologics company said the decision,...
22:29 , May 31, 2018 |  BC Extra  |  Company News

Management tracks: Axcella, Arcturus, Orexo

Metabolic dysregulation company Axcella Health Inc. (Cambridge, Mass.) hired William Hinshaw as president and CEO. He was EVP and head of U.S. oncology at Novartis AG (NYSE:NVS; SIX:NOVN). RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT)...
19:58 , Mar 9, 2018 |  BC Week In Review  |  Company News

Arcturus fails to nominate FY17 statement auditor

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said its shareholders did not ratify the appointment of Ernst & Young as independent auditors of the RNA therapeutics company’s 2017 financial statements, which could delay or altogether prevent filing of...
18:48 , Feb 8, 2018 |  BC Extra  |  Company News

Management tracks: CRISPR, Arcturus

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) said CSO Bill Lundberg is stepping down. He will become head of CRISPR's scientific advisory board. RNA therapeutics company Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said President and CEO Joseph...
21:54 , Dec 1, 2017 |  BC Week In Review  |  Company News

Arcturus, Synthetic Genomics partner for RNA-based vaccines

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) granted Synthetic Genomics Inc. (La Jolla, Calif.) exclusive, worldwide rights to its LUNAR lipid-mediated delivery technology to develop self-amplifying RNA-based vaccines and therapeutics for humans and animals based on Synthetic Genomics'...
21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
19:21 , Oct 20, 2017 |  BC Week In Review  |  Company News

HemoShear, Takeda in liver disease deal

HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive undisclosed upfront payments and R&D funding and is...
11:06 , Oct 17, 2017 |  BC Extra  |  Company News

HemoShear, Takeda in liver disease deal

HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive undisclosed upfront payments and R&D funding and is...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
17:55 , Oct 6, 2017 |  BC Week In Review  |  Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...